The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participants with Change in Symptomatic Intracranial Hemorrhage
Timeframe: Hour 36
Participants with Parenchymal Hematoma Type 1
Timeframe: 24 Hours
Participants with Parenchymal Hematoma Type 2
Timeframe: 24 Hours
30-Day Mortality Count
Timeframe: Day 30
90-Day Mortality Count
Timeframe: Day 90
Number of Grade 3 Adverse Events
Timeframe: Hour 24
Number of Grade 3 Adverse Events
Timeframe: Day 5
Number of Grade 3 Adverse Events
Timeframe: Day 30
Number of Grade 3 Adverse Events
Timeframe: Day 90